RU2708247C2 - Соединение для лечения рака - Google Patents

Соединение для лечения рака Download PDF

Info

Publication number
RU2708247C2
RU2708247C2 RU2015142102A RU2015142102A RU2708247C2 RU 2708247 C2 RU2708247 C2 RU 2708247C2 RU 2015142102 A RU2015142102 A RU 2015142102A RU 2015142102 A RU2015142102 A RU 2015142102A RU 2708247 C2 RU2708247 C2 RU 2708247C2
Authority
RU
Russia
Prior art keywords
cancer
another embodiment
inhibitor
compound
braf
Prior art date
Application number
RU2015142102A
Other languages
English (en)
Russian (ru)
Other versions
RU2015142102A3 (enExample
RU2015142102A (ru
Inventor
Цзин Ван
Цзяньцзунь ЧЭНЬ
Дуэйн Д. Миллер
Вей Ли
Original Assignee
Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Теннесси Рисерч Фаундейшн filed Critical Юниверсити Оф Теннесси Рисерч Фаундейшн
Publication of RU2015142102A publication Critical patent/RU2015142102A/ru
Publication of RU2015142102A3 publication Critical patent/RU2015142102A3/ru
Application granted granted Critical
Publication of RU2708247C2 publication Critical patent/RU2708247C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2015142102A 2013-03-05 2014-03-05 Соединение для лечения рака RU2708247C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
US61/772,885 2013-03-05
PCT/US2014/020858 WO2014138279A1 (en) 2013-03-05 2014-03-05 Compounds for treatment of cancer

Publications (3)

Publication Number Publication Date
RU2015142102A RU2015142102A (ru) 2017-04-07
RU2015142102A3 RU2015142102A3 (enExample) 2018-03-13
RU2708247C2 true RU2708247C2 (ru) 2019-12-05

Family

ID=51491914

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015142102A RU2708247C2 (ru) 2013-03-05 2014-03-05 Соединение для лечения рака

Country Status (11)

Country Link
US (2) US10022356B2 (enExample)
EP (1) EP2964028A4 (enExample)
JP (2) JP6835472B2 (enExample)
KR (1) KR102246652B1 (enExample)
CN (2) CN105163584B (enExample)
AU (2) AU2014225761B2 (enExample)
CA (1) CA2904338C (enExample)
IL (1) IL241232B (enExample)
MX (2) MX375059B (enExample)
RU (1) RU2708247C2 (enExample)
WO (1) WO2014138279A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2854184C1 (ru) * 2025-07-04 2025-12-29 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Способ получения [2-(1H-индол-3-ил)-1H-имидазол-4-ил](3,4,5-триметоксифенил)метанона (сабизабулина)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
MX379271B (es) 2014-05-06 2025-03-11 Gtx Inc Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
CA2972189A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
IL256111B2 (en) * 2015-06-05 2023-09-01 Univ Illinois Treatment of pac combinations
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
US20180369203A1 (en) * 2015-07-09 2018-12-27 The Jackson Laboratory Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
WO2017024207A1 (en) * 2015-08-06 2017-02-09 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
US10821112B2 (en) 2016-03-16 2020-11-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
EP3571200B8 (en) 2017-01-17 2022-08-03 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7140103B2 (ja) * 2017-03-10 2022-09-21 コニカミノルタ株式会社 治療有効性の予測方法
US11883491B2 (en) 2017-05-03 2024-01-30 St. Jude Children's Research Hospital, Inc. Compositions and methods for prevention and treatment of hearing loss
IL274663B2 (en) 2017-11-17 2024-01-01 Univ Illinois Cancer therapy by degrading dual mek signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
WO2019222385A1 (en) * 2018-05-15 2019-11-21 University Of Tennessee Research Foundation Compounds for treatment of triple negative breast cancer and ovarian cancer
US20190374512A1 (en) * 2018-05-15 2019-12-12 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
CN113329749B (zh) 2018-10-05 2025-02-11 伊利诺伊大学董事会 用于治疗葡萄膜黑色素瘤的联合疗法
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
JP2023513015A (ja) * 2020-01-31 2023-03-30 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
WO2024036114A2 (en) * 2022-08-08 2024-02-15 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146555A1 (en) * 2004-06-18 2008-06-19 Gpc Biotech, Inc Uses of Kinase Inhibitors and Compositions Thereof
US20120053185A1 (en) * 2010-08-27 2012-03-01 CollabRx Inc. Method to treat melanoma in braf inhibitor-resistant subjects
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2829451B2 (ja) 1990-11-30 1998-11-25 大塚製薬株式会社 活性酸素抑制剤
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2003027105A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
WO2004093873A1 (en) 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004103960A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
CN1902184A (zh) 2003-11-18 2007-01-24 田纳西大学研究基金会 噻唑烷酮酰胺、噻唑烷羧酸酰胺、其制备方法及其用途
WO2005058834A2 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
US20070191448A1 (en) 2004-03-08 2007-08-16 Robert Zelle Ion channel modulators
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
EP2395004B1 (en) * 2005-06-22 2016-01-20 Plexxikon Inc. Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
EP2025347A4 (en) 2006-05-15 2010-08-11 Takeda Pharmaceutical PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
MX2010014066A (es) 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
PL3560498T3 (pl) * 2009-10-16 2022-12-12 Novartis Ag Kombinacja zawierająca inhibitor mek i inhibitor b-raf
RU2581367C2 (ru) * 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
CN103443725B (zh) 2011-03-29 2015-07-29 三菱电机株式会社 伺服控制装置的异常诊断装置及异常诊断系统
SG194052A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and erlotinib, and methods of use
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146555A1 (en) * 2004-06-18 2008-06-19 Gpc Biotech, Inc Uses of Kinase Inhibitors and Compositions Thereof
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
US20120053185A1 (en) * 2010-08-27 2012-03-01 CollabRx Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WATANABE K. et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models//Clin Cancer Res. 2010 Feb 15;16(4):1170-8. doi: 10.1158/1078-0432.CCR-09-2482. Epub 2010 Feb 9.PMID: 20145173 DOI: 10.1158/1078-0432.CCR-09-2482 *
WATANABE K. et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models//Clin Cancer Res. 2010 Feb 15;16(4):1170-8. doi: 10.1158/1078-0432.CCR-09-2482. Epub 2010 Feb 9.PMID: 20145173 DOI: 10.1158/1078-0432.CCR-09-2482. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2854184C1 (ru) * 2025-07-04 2025-12-29 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Способ получения [2-(1H-индол-3-ил)-1H-имидазол-4-ил](3,4,5-триметоксифенил)метанона (сабизабулина)

Also Published As

Publication number Publication date
KR20150123328A (ko) 2015-11-03
RU2015142102A3 (enExample) 2018-03-13
MX2020009256A (es) 2020-10-28
AU2014225761B2 (en) 2018-06-07
CN105163584A (zh) 2015-12-16
MX375059B (es) 2025-03-06
AU2014225761A1 (en) 2015-10-08
CA2904338A1 (en) 2014-09-12
US20160015688A1 (en) 2016-01-21
IL241232A0 (en) 2015-11-30
CN105163584B (zh) 2019-06-04
EP2964028A4 (en) 2017-06-07
CA2904338C (en) 2022-07-05
RU2015142102A (ru) 2017-04-07
JP6835472B2 (ja) 2021-02-24
KR102246652B1 (ko) 2021-04-29
AU2018226470A1 (en) 2018-09-27
WO2014138279A1 (en) 2014-09-12
JP2019077727A (ja) 2019-05-23
US20180325872A1 (en) 2018-11-15
US10525037B2 (en) 2020-01-07
EP2964028A1 (en) 2016-01-13
US10022356B2 (en) 2018-07-17
IL241232B (en) 2021-02-28
MX2015011713A (es) 2016-05-09
JP2016510748A (ja) 2016-04-11
AU2018226470B2 (en) 2019-11-28
CN109568312A (zh) 2019-04-05

Similar Documents

Publication Publication Date Title
RU2708247C2 (ru) Соединение для лечения рака
JP2023504230A (ja) Ｐｒｍｔ５阻害剤の組合せ医薬
KR20180006447A (ko) Braf-v600-관련 질환의 치료에 사용하기 위한 plx-8394 또는 plx-7904
CN105120868A (zh) 组合治疗
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
CN108779073A (zh) 用于治疗癌症的组合物和方法
JP2021107456A (ja) インドリノン化合物の使用
EP3793549A1 (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
RU2015108755A (ru) Комбинация ингибитора pik3 и ингибитора с-мет
US11439625B2 (en) Combination therapy for proliferative diseases
KR20210060549A (ko) 유방암 치료를 위한 TGFβ 억제제 및 CDK 억제제의 조합
JP5945863B2 (ja) 腎細胞がん治療剤
KR20250166103A (ko) 종양 치료용 약제학적 조성물
US11389434B2 (en) Methods and pharmaceutical compositions for the treatment of mast cell diseases
HK40005718A (en) Compounds for treatment of cancer
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合